Martin Bidlingmaier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4636907/publications.pdf

Version: 2024-02-01

217 12,159 56
papers citations h-index

219 219 219 12432 all docs docs citations times ranked citing authors

101

g-index

#	Article	IF	Citations
1	Growth Hormone Receptor <i>(GHR)</i> 6Ω Pseudoexon Activation: A Novel Cause of Severe Growth Hormone Insensitivity. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e401-e416.	1.8	4
2	Association of renin and aldosterone with glucose metabolism in a Western European population: the KORA F4/FF4 study. BMJ Open Diabetes Research and Care, 2022, 10, e002558.	1.2	5
3	The role of adrenal venous sampling (AVS) in primary bilateral macronodular adrenocortical hyperplasia (PBMAH): a study of 16 patients. Endocrine, 2022, 76, 434-445.	1.1	9
4	The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2027-e2036.	1.8	27
5	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. European Journal of Endocrinology, 2022, 186, P35-P52.	1.9	42
6	Differences in the Distribution of IGF-I Concentrations Between European and US Populations. Journal of the Endocrine Society, 2022, 6 , .	0.1	3
7	Married but lonely. Impact of poor marital quality on diurnal cortisol patterns in older people: findings from the cross-sectional KORA-Age study. Stress, 2021, 24, 36-43.	0.8	7
8	Growth hormone receptor knockout to reduce the size of donor pigs for preclinical xenotransplantation studies. Xenotransplantation, 2021, 28, e12664.	1.6	38
9	Principles of laboratory investigation for pituitary hormones. , 2021, , 23-35.		O
10	The Use of IGF-I to Monitor Long-Acting Growth Hormone Therapyâ€"Timing is an Art…. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2367-e2369.	1.8	8
11	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
12	Circulating microRNA Expression in Cushing's Syndrome. Frontiers in Endocrinology, 2021, 12, 620012.	1.5	11
13	Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2887-e2899.	1.8	5
14	Characteristics of preoperative steroid profiles and glucose metabolism in patients with primary aldosteronism developing adrenal insufficiency after adrenalectomy. Scientific Reports, 2021, 11, 11181.	1.6	6
15	Salivary Profiles of 11-oxygenated Androgens Follow a Diurnal Rhythm in Patients With Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4509-e4519.	1.8	11
16	Chronic Inflammation Mediates the Association between Cortisol and Hyperglycemia: Findings from the Cross-Sectional Population-Based KORA Age Study. Journal of Clinical Medicine, 2021, 10, 2751.	1.0	5
17	MECHANISMS IN ENDOCRINOLOGY: Transient juvenile hypoglycemia in growth hormone receptor deficiency – mechanistic insights from Laron syndrome and tailored animal models. European Journal of Endocrinology, 2021, 185, R35-R47.	1.9	9
18	11-oxygenated androgens and their relation to hypothalamus-pituitary-gonadal-axis disturbances in adults with congenital adrenal hyperplasia. Journal of Steroid Biochemistry and Molecular Biology, 2021, 212, 105921.	1.2	13

#	Article	IF	Citations
19	Reverse circadian glucocorticoid treatment in prepubertal children with congenital adrenal hyperplasia. Journal of Pediatric Endocrinology and Metabolism, 2021, 34, 1543-1548.	0.4	5
20	Influence of IGF-I serum concentration on muscular regeneration capacity in patients with sarcopenia. BMC Musculoskeletal Disorders, 2021, 22, 807.	0.8	7
21	Single-Center Prospective Cohort Study on the Histopathology, Genotype, and Postsurgical Outcomes of Patients With Primary Aldosteronism. Hypertension, 2021, 78, 738-746.	1.3	35
22	IGF-I/IGFBP3/ALS Deficiency in Sarcopenia: Low GHBP Suggests GH Resistance in a Subgroup of Geriatric Patients. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1698-1707.	1.8	13
23	Primary and Secondary Hyperparathyroidism in Patients with Primary Aldosteronism – Findings From the German Conn's Registry. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 246-254.	0.6	14
24	Steroid 17-Hydroxyprogesterone in Hair Is a Potential Long-Term Biomarker of Androgen Control in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. Neuroendocrinology, 2020, 110, 938-949.	1.2	10
25	Persisting Muscle Dysfunction in Cushing's Syndrome Despite Biochemical Remission. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4490-e4498.	1.8	29
26	Motivation for and adherence to growth hormone replacement therapy in adults with hypopituitarism: the patients $\hat{a} \in \mathbb{R}^{\infty}$ perspective. Pituitary, 2020, 23, 479-487.	1.6	9
27	The Impact of Glucocorticoid Co-Secretion in Primary Aldosteronism on Thyroid Autoantibody Titers During the Course of Disease. Hormone and Metabolic Research, 2020, 52, 404-411.	0.7	6
28	Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. Endocrine, 2020, 69, 625-633.	1.1	10
29	Functional changes of the liver in the absence of growth hormone (GH) action – Proteomic and metabolomic insights from a GH receptor deficient pig model. Molecular Metabolism, 2020, 36, 100978.	3.0	23
30	Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference. Clinica Chimica Acta, 2020, 507, 98-103.	0.5	8
31	Altered metabolic and hormonal responses to moderate exercise in overweight/obesity. Metabolism: Clinical and Experimental, 2020, 107, 154219.	1.5	18
32	Laboratory investigations in the diagnosis and follow-up of GH-related disorders. Archives of Endocrinology and Metabolism, 2020, 63, 618-629.	0.3	29
33	A Proposal for the Interpretation of Serum IGF-I Concentration as Part of Laboratory Screening in Children with Growth Failure. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2020, 12, 130-139.	0.4	20
34	Acromegaly caused by lung carcinoid with ectopic GHRH secretion. Polish Archives of Internal Medicine, 2020, 130, 685-687.	0.3	4
35	Prospective evaluation of aldosterone LC-MS/MS-specific cutoffs for the saline infusion test. European Journal of Endocrinology, 2020, 183, 191-201.	1.9	8
36	Adrenal Insufficiency After Unilateral Adrenalectomy in Primary Aldosteronism: Long-Term Outcome and Clinical Impact. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5658-5664.	1.8	37

#	Article	IF	Citations
37	Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronismâ€"a Review. Current Hypertension Reports, 2019, 21, 77.	1.5	17
38	Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective. Hormone Research in Paediatrics, 2019, 92, 1-14.	0.8	181
39	Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3192-3202.	1.8	72
40	Performance of LC–MS/MS and immunoassay based 24-h urine free cortisol in the diagnosis of Cushing's syndrome. Journal of Steroid Biochemistry and Molecular Biology, 2019, 190, 193-197.	1.2	24
41	Toward a Diagnostic Score in Cushing's Syndrome. Frontiers in Endocrinology, 2019, 10, 766.	1.5	46
42	Aldosterone to Renin Ratio as Screening Tool in Primary Aldosteronism. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 84-92.	0.6	21
43	Determinants of the growth hormone nadir during oral glucose tolerance test in adults. European Journal of Endocrinology, 2019, 181, 55-67.	1.9	42
44	Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections, 2018, 7, R126-R134.	0.8	39
45	IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea. Endocrine, 2018, 60, 317-322.	1.1	12
46	GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome. Growth Hormone and IGF Research, 2018, 39, 13-18.	0.5	3
47	Biomarkers of GH action in children and adults. Growth Hormone and IGF Research, 2018, 40, 1-8.	0.5	7
48	Control of (pre)-analytical aspects in immunoassay measurements of metabolic hormones in rodents. Endocrine Connections, 2018, 7, R147-R159.	0.8	8
49	Growth hormone receptor-deficient pigs resemble the pathophysiology of human Laron syndrome and reveal altered activation of signaling cascades in the liver. Molecular Metabolism, 2018, 11, 113-128.	3.0	79
50	Quantification of 1,25-dihydroxyvitamin D – value of manufacturers' product information. Clinical Chemistry and Laboratory Medicine, 2018, 56, e46-e49.	1.4	0
51	Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping Patients with Cushing Syndrome. Clinical Chemistry, 2018, 64, 586-596.	1.5	70
52	Growth hormone: isoforms, clinical aspects and assays interference. Clinical Diabetes and Endocrinology, 2018, 4, 18.	1.3	26
53	Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4543-4552.	1.8	47
54	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. European Journal of Endocrinology, 2018, 179, 97-108.	1.9	27

#	Article	IF	Citations
55	Impairment of Host Liver Repopulation by Transplanted Hepatocytes in Aged Rats and the Release by Short-Term Growth Hormone Treatment. American Journal of Pathology, 2017, 187, 553-569.	1.9	2
56	Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary, 2017, 20, 33-45.	1.6	33
57	Assessment of lung function in a large cohort of patients with acromegaly. European Journal of Endocrinology, 2017, 177, 15-23.	1.9	8
58	TNFα drives mitochondrial stress in POMC neurons in obesity. Nature Communications, 2017, 8, 15143.	5.8	92
59	Acute administration of acyl, but not desacyl ghrelin, decreases blood pressure in healthy humans. European Journal of Endocrinology, 2017, 176, 123-132.	1.9	21
60	Dietary sugars, not lipids, drive hypothalamic inflammation. Molecular Metabolism, 2017, 6, 897-908.	3.0	104
61	MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults. European Journal of Endocrinology, 2017, 176, 283-294.	1.9	44
62	Anthropometric factors have significant influence on the outcome of the GHRH–arginine test: establishment of normative data for an automated immunoassay specifically measuring 22 kDa human growth hormone. European Journal of Endocrinology, 2017, 176, 273-281.	1.9	8
63	Human placental growth hormone in ectopic pregnancy: Detection in maternal blood, immunohistochemistry and potential clinical implication. Growth Hormone and IGF Research, 2017, 37, 13-18.	0.5	3
64	Cushing's syndrome: a model for sarcopenic obesity. Endocrine, 2017, 57, 481-485.	1.1	26
65	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight, 2017, 2, .	2.3	187
66	Spotting the Cheaters. Clinical Chemistry, 2016, 62, 1296-1298.	1.5	1
67	Quality assurance in the analysis of growth hormone and insulin-like growth factor I in disorders of the somatotropic axis. Laboratoriums Medizin, $2016, 39, \ldots$	0.1	0
68	Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. European Journal of Endocrinology, 2016, 174, C1-C8.	1.9	99
69	Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine, 2016, 54, 198-205.	1.1	22
70	Genomewide metaâ€analysis identifies loci associated with <scp>IGF</scp> â€l and <scp>IGFBP</scp> â€3 levels with impact on ageâ€related traits. Aging Cell, 2016, 15, 811-824.	3.0	83
71	In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells. Endocrine-Related Cancer, 2016, 23, 509-519.	1.6	10
72	Mass Spectrometry–Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. Clinical Chemistry, 2016, 62, 514-524.	1.5	123

#	Article	IF	CITATIONS
73	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. Hypertension, 2016, 67, 139-145.	1.3	127
74	Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. European Journal of Endocrinology, 2016, 174, 355-362.	1.9	56
75	Obesity in MENX Rats Is Accompanied by High Circulating Levels of Ghrelin and Improved Insulin Sensitivity. Diabetes, 2016, 65, 406-420.	0.3	10
76	Pegvisomant-primed glucagon stimulation test in assessing GH reserve and GH/IGF kinetics in adults suspected of GH deficiency. Pituitary, 2016, 19, 65-74.	1.6	4
77	Low-carbohydrate, high-fat diets have sex-specific effects on bone health in rats. European Journal of Nutrition, 2016, 55, 2307-2320.	1.8	18
78	Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. Journal of Hypertension, 2015, 33, 2500-2511.	0.3	50
79	CT mapping of the vertebral level of right adrenal vein. Diagnostic and Interventional Radiology, 2015, 21, 60-66.	0.7	23
80	QualitÃtssicherung der Analytik von Wachstumshormon und Insulin-Like Growth Factor I bei Erkrankungen der somatotropen Achse. Laboratoriums Medizin, 2015, 39, .	0.1	0
81	Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. Hypertension, 2015, 66, 248-253.	1.3	10
82	Pitfalls of Insulin-like Growth Factor-I and Growth Hormone Assays. Endocrinology and Metabolism Clinics of North America, 2015, 44, 27-34.	1.2	45
83	Prognostic Value of Aldosterone and Cortisol in Patients Hospitalized for Acutely Decompensated Chronic Heart Failure With and Without Mineralocorticoid Receptor Antagonism. Journal of Cardiac Failure, 2015, 21, 208-216.	0.7	17
84	Nicotine enhances modulation of foodâ€cue reactivity by leptin and ghrelin in the ventromedial prefrontal cortex. Addiction Biology, 2015, 20, 832-844.	1.4	28
85	Human placental growth hormone: A potential new biomarker in gestational trophoblastic disease. Gynecologic Oncology, 2015, 136, 264-268.	0.6	9
86	Time to Recovery of Adrenal Function After Curative Surgery for Cushing's Syndrome Depends on Etiology. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1300-1308.	1.8	65
87	Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1699-1708.	1.8	144
88	Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. European Journal of Endocrinology, 2015, 172, 251-260.	1.9	47
89	Genome-Wide Meta-Analyses of Plasma Renin Activity and Concentration Reveal Association With the Kininogen 1 and Prekallikrein Genes. Circulation: Cardiovascular Genetics, 2015, 8, 131-140.	5.1	24
90	Oxytocin-induced coping with stressful life events in old age depends on attachment: Findings from the cross-sectional KORA Age study. Psychoneuroendocrinology, 2015, 56, 132-142.	1.3	11

#	Article	IF	Citations
91	Growth hormone binding protein $\hat{a}\in$ Physiological and analytical aspects. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 671-683.	2.2	30
92	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1262-E1269.	1.8	4
93	Genome-wide association and functional studies identify a role for <i>IGFBP3</i> in hip osteoarthritis. Annals of the Rheumatic Diseases, 2015, 74, 1861-1867.	0.5	47
94	Age Below 40 or a Recently Proposed Clinical Prediction Score Cannot Bypass Adrenal Venous Sampling in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1035-E1039.	1.8	95
95	Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: A cross-sectional study. World Journal of Biological Psychiatry, 2014, 15, 26-35.	1.3	62
96	Nicotine administration in healthy non-smokers reduces appetite but does not alter plasma ghrelin. Human Psychopharmacology, 2014, 29, 384-387.	0.7	24
97	Diastrophic Dysplasia Sulfate Transporter (SLC26A2) Is Expressed in the Adrenal Cortex and Regulates Aldosterone Secretion. Hypertension, 2014, 63, 1102-1109.	1.3	21
98	Effects of low-carbohydrate, high-fat diets on apparent digestibility of minerals and trace elements in rats. Nutrition, 2014, 30, 869-875.	1.1	34
99	Effects of low carbohydrate diets on energy and nitrogen balance and body composition in rats depend on dietary protein-to-energy ratio. Nutrition, 2014, 30, 863-868.	1.1	11
100	A High Aldosterone to Renin Ratio Is Associated With High Serum Parathyroid Hormone Concentrations in the General Population. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 965-971.	1.8	35
101	Age- and Sex-Specific Reference Intervals Across Life Span for Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 Ratio Measured by New Automated Chemiluminescence Assays. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1675-1686.	1.8	104
102	Reference Intervals for Insulin-like Growth Factor-1 (IGF-I) From Birth to Senescence: Results From a Multicenter Study Using a New Automated Chemiluminescence IGF-I Immunoassay Conforming to Recent International Recommendations. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1712-1721.	1.8	289
103	A Robust Method for Genomeâ€Wide Association Metaâ€Analysis With the Application to Circulating Insulinâ€Like Growth Factor I Concentrations. Genetic Epidemiology, 2014, 38, 162-171.	0.6	5
104	Acute Administration of Unacylated Ghrelin Has No Effect on Basal or Stimulated Insulin Secretion in Healthy Humans. Diabetes, 2014, 63, 2309-2319.	0.3	42
105	Validation of serum IGF-I as a biomarker to monitor exogenous growth hormone agonist and antagonist bioactivity in rabbits. DMM Disease Models and Mechanisms, 2014, 7, 1263-73.	1.2	15
106	(Still) longing for food: Insulin reactivity modulates response to food pictures. Human Brain Mapping, 2013, 34, 2367-2380.	1.9	89
107	Impaired glucose tolerance in rats fed low-carbohydrate, high-fat diets. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E1059-E1070.	1.8	58
108	Fasting levels of ghrelin covary with the brain response to food pictures. Addiction Biology, 2013, 18, 855-862.	1.4	100

#	Article	IF	Citations
109	Influence of pre-analytical conditions on the measurement of components of the GH/IGF axis in rats. Growth Hormone and IGF Research, 2013, 23, 141-148.	0.5	3
110	Lack of influence of somatic mutations on steroid gradients during adrenal vein sampling in aldosterone-producing adenoma patients. European Journal of Endocrinology, 2013, 169, 657-663.	1.9	22
111	Aldosterone Excess Impairs First Phase Insulin Secretion in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2513-2520.	1.8	80
112	The orphan receptor Gpr83 regulates systemic energy metabolism via ghrelin-dependent and ghrelin-independent mechanisms. Nature Communications, 2013, 4, 1968.	5.8	64
113	Roux-en-Y Gastric Bypass Surgery But Not Vertical Sleeve Gastrectomy Decreases Bone Mass in Male Rats. Endocrinology, 2013, 154, 2015-2024.	1.4	60
114	Gaps in the Traceability Chain of Human Growth Hormone Measurements. Clinical Chemistry, 2013, 59, 1074-1082.	1.5	18
115	Physiologic Concentrations of Exogenously Infused Ghrelin Reduces Insulin Secretion Without Affecting Insulin Sensitivity in Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2536-2543.	1.8	47
116	Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. European Heart Journal, 2013, 34, 578-587.	1.0	46
117	A Genome-Wide Association Meta-Analysis of Circulating Sex Hormone–Binding Globulin Reveals Multiple Loci Implicated in Sex Steroid Hormone Regulation. PLoS Genetics, 2012, 8, e1002805.	1.5	151
118	Ghrelin Stimulation of Growth Hormone Isoforms: Parallel Secretion of Total and 20-kDa Growth Hormone and Relation to Insulin Sensitivity in Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3366-3374.	1.8	12
119	Gender-, strain-, and inheritance-dependent variation in aldosterone secretion in mice. Journal of Endocrinology, 2012, 215, 375-381.	1.2	11
120	Three-Year Efficacy and Safety of LB03002, a Once-Weekly Sustained-Release Growth Hormone (GH) Preparation, in Prepubertal Children with GH Deficiency (GHD). Journal of Clinical Endocrinology and Metabolism, 2012, 97, 400-407.	1.8	66
121	New Detection Methods of Growth Hormone and Growth Factors. Endocrine Development, 2012, 23, 52-59.	1.3	12
122	Prolonged Zona Glomerulosa Insufficiency Causing Hyperkalemia in Primary Aldosteronism after Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3965-3973.	1.8	73
123	Observational Study Mortality in Treated Primary Aldosteronism. Hypertension, 2012, 60, 618-624.	1.3	235
124	Labordiagnostik bei Wachstumshormon-assoziierten Erkrankungen/Biochemical diagnosis of growth hormone related diseases. Laboratoriums Medizin, 2012, 36, 179-185.	0.1	0
125		0.1	0
126	Altered Psychobiological Responsiveness in Women With Irritable Bowel Syndrome. Psychosomatic Medicine, 2012, 74, 221-231.	1.3	35

#	Article	IF	CITATIONS
127	Quality of life in patients with primary aldosteronism: Gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. Journal of Psychiatric Research, 2012, 46, 1650-1654.	1.5	47
128	Automated 22-kD Growth Hormone–Specific Assay without Interference from Pegvisomant. Clinical Chemistry, 2012, 58, 1446-1456.	1.5	59
129	A guide for measurement of circulating metabolic hormones in rodents: Pitfalls during the pre-analytical phase. Molecular Metabolism, 2012, 1, 47-60.	3.0	41
130	The GOAT-Ghrelin System Is Not Essential for Hypoglycemia Prevention during Prolonged Calorie Restriction. PLoS ONE, 2012, 7, e32100.	1.1	48
131	Isoenergetic Feeding of Low Carbohydrate-High Fat Diets Does Not Increase Brown Adipose Tissue Thermogenic Capacity in Rats. PLoS ONE, 2012, 7, e38997.	1.1	18
132	Phenotype Selection Reveals Coevolution of Muscle Glycogen and Protein and PTEN as a Gate Keeper for the Accretion of Muscle Mass in Adult Female Mice. PLoS ONE, 2012, 7, e39711.	1.1	9
133	Low-dose ghrelin infusion — Evidence against a hormonal role in food intake. Regulatory Peptides, 2012, 174, 26-31.	1.9	27
134	Low-carbohydrate high-fat diets in combination with daily exercise in rats: Effects on body weight regulation, body composition and exercise capacity. Physiology and Behavior, 2012, 106, 185-192.	1.0	24
135	Spontaneous remission of idiopathic aldosteronism after longâ€term treatment with spironolactone: results from the German Conn's Registry. Clinical Endocrinology, 2012, 76, 473-477.	1.2	25
136	Carbohydrate Content of Post-operative Diet Influences the Effect of Vertical Sleeve Gastrectomy on Body Weight Reduction in Obese Rats. Obesity Surgery, 2012, 22, 140-151.	1.1	8
137	Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary, 2012, 15, 97-100.	1.6	26
138	An interaction between a neuropeptide Y gene polymorphism and early adversity modulates endocrine stress responses. Psychoneuroendocrinology, 2011, 36, 1010-1020.	1.3	47
139	Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 43-48.	2.6	75
140	A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Human Molecular Genetics, 2011, 20, 1241-1251.	1.4	67
141	Utilization of a Mutagenesis Screen to Generate Mouse Models of Hyperaldosteronism. Endocrinology, 2011, 152, 326-331.	1.4	7
142	Serum IGF-I Is Not a Reliable Pharmacodynamic Marker of Exogenous Growth Hormone Activity in Mice. Endocrinology, 2011, 152, 4764-4776.	1.4	22
143	Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. European Journal of Endocrinology, 2011, 165, 301-306.	1.9	93
144	Harmonization of growth hormone measurements with different immunoassays by data adjustment. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1135-42.	1.4	40

#	Article	IF	Citations
145	Failure of Urine Dipsticks to Detect Ketosis in Rats. Obesity Facts, 2011, 4, 81-82.	1.6	О
146	Adrenal Venous Sampling. Hypertension, 2011, 57, 990-995.	1.3	208
147	Association of plasma aldosterone with the metabolic syndrome in two German populations. European Journal of Endocrinology, 2011, 164, 751-758.	1.9	51
148	Lack of Dietary Carbohydrates Induces Hepatic Growth Hormone (GH) Resistance in Rats. Endocrinology, 2011, 152, 1948-1960.	1.4	35
149	Genetic Determinants of Serum Testosterone Concentrations in Men. PLoS Genetics, 2011, 7, e1002313.	1.5	178
150	Induction of ketosis in rats fed low-carbohydrate, high-fat diets depends on the relative abundance of dietary fat and protein. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E65-E76.	1.8	76
151	Problems with Growth Hormone Doping in Sports: Isoform Methods. Growth Hormone, 2011, , 131-137.	0.2	0
152	Predicting metabolisable energy in commercial rat diets: physiological fuel values may be misleading. British Journal of Nutrition, 2010, 103, 1525-1533.	1.2	14
153	Short-term exposure to low-carbohydrate, high-fat diets induces low bone mineral density and reduces bone formation in rats. Journal of Bone and Mineral Research, 2010, 25, 275-284.	3.1	73
154	Purification of recombinant growth hormone by clear native gels for conformational analyses: preservation of conformation and receptor binding. Amino Acids, 2010, 39, 859-869.	1.2	8
155	Mental health in the aged: prevalence, covariates and related neuroendocrine, cardiovascular and inflammatory factors of successful aging. BMC Medical Research Methodology, 2010, 10, 36.	1.4	41
156	Quantification of growth hormone in serum by isotope dilution mass spectrometry. Analytical Biochemistry, 2010, 401, 228-235.	1.1	56
157	Ghrelin Suppresses Glucose-Stimulated Insulin Secretion and Deteriorates Glucose Tolerance in Healthy Humans. Diabetes, 2010, 59, 2145-2151.	0.3	281
158	A Pegylated Growth Hormone Receptor Antagonist, Pegvisomant, Does Not Enter the Brain in Humans. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3844-3847.	1.8	14
159	Growth Hormone and Insulin-Like Growth Factor I Insensitivity of Fibroblasts Isolated from a Patient with an llºBl± Mutation. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1220-1228.	1.8	36
160	Isolated GH Deficiency Type II: Knockdown of the Harmful Δ3GH Recovers wt-GH Secretion in Rat Tumor Pituitary Cells. Endocrinology, 2010, 151, 4400-4409.	1.4	13
161	Detecting Growth Hormone Abuse in Athletes. Endocrinology and Metabolism Clinics of North America, 2010, 39, 25-32.	1.2	11
162	Measurement of human growth hormone by immunoassays: Current status, unsolved problems and clinical consequences. Growth Hormone and IGF Research, 2010, 20, 19-25.	0.5	107

#	Article	IF	Citations
163	Specific monoclonal antibodies and ultrasensitive immunoassays for 20K and 22K human growth hormone. Growth Hormone and IGF Research, 2010, 20, 239-244.	0.5	13
164	A microsphere-based duplex competitive immunoassay for the simultaneous measurements of aldosterone and testosterone in small sample volumes: Validation in human and mouse plasma. Steroids, 2010, 75, 1089-1096.	0.8	20
165	Total Adrenal Volume But Not Testicular Adrenal Rest Tumor Volume Is Associated with Hormonal Control in Patients with 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2065-2072.	1.8	80
166	Pitfalls of Insulin-Like Growth Factor I Assays. Hormone Research in Paediatrics, 2009, 71, 30-33.	0.8	25
167	Risk Factors Associated with a Low Glomerular Filtration Rate in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 869-875.	1.8	166
168	Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. European Journal of Endocrinology, 2009, 160, 349-355.	1.9	39
169	Short term regulation of aldosterone secretion after stimulation and suppression experiments in mice. Journal of Molecular Endocrinology, 2009, 42, 407-413.	1.1	18
170	Chronic Growth Hormone Excess Is Associated with Increased Aldosterone: A Study in Patients with Acromegaly and in Growth Hormone Transgenic Mice. Experimental Biology and Medicine, 2009, 234, 1002-1009.	1.1	27
171	Lowâ€carbohydrate Highâ€fat Diets: Regulation of Energy Balance and Body Weight Regain in Rats. Obesity, 2009, 17, 283-289.	1.5	21
172	High Prevalence of Reduced Fecundity in Men with Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1665-1670.	1.8	151
173	High-Sensitivity Chemiluminescence Immunoassays for Detection of Growth Hormone Doping in Sports. Clinical Chemistry, 2009, 55, 445-453.	1.5	123
174	Growth Hormone. Handbook of Experimental Pharmacology, 2009, , 187-200.	0.9	46
175	The Diagnosis and Treatment of Primary Hyperaldosteronism in Germany. Deutsches Ärzteblatt International, 2009, 106, 305-11.	0.6	47
176	Herausgeber und Autoren. , 2009, , VII-IX.		0
177	The relationship between alexithymia and salivary cortisol levels in somatoform disorders. Nordic Journal of Psychiatry, 2008, 62, 366-373.	0.7	19
178	Systemic response of the GH/IGF-I axis in timely versus delayed fracture healing. Growth Hormone and IGF Research, 2008, 18, 205-212.	0.5	38
179	Problems with GH assays and strategies toward standardization. European Journal of Endocrinology, 2008, 159, S41-S44.	1.9	48
180	Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly. European Journal of Endocrinology, 2007, 156, 331-339.	1.9	12

#	Article	IF	Citations
181	Technology Insight: detecting growth hormone abuse in athletes. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 769-777.	2.9	31
182	The Diagnosis of Partial Growth Hormone Deficiency in Adults with a Putative Insult to the Hypothalamo-Pituitary Axis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1705-1709.	1.8	23
183	Treatment of Acromegaly with Pegvisomant during Pregnancy: Maternal and Fetal Effects. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3374-3377.	1.8	81
184	Preanalytical Stability of Adrenocorticotropic Hormone Depends on Time to Centrifugation Rather than Temperature. Clinical Chemistry, 2007, 53, 358-359.	1.5	33
185	Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. European Journal of Endocrinology, 2007, 156, 647-653.	1.9	51
186	Increased acylated plasma ghrelin, but improved lipid profiles 24-h after consumption of carob pulp preparation rich in dietary fibre and polyphenols. British Journal of Nutrition, 2007, 98, 1170-1177.	1.2	30
187	What Endocrinologists Should Know About Growth Hormone Measurements. Endocrinology and Metabolism Clinics of North America, 2007, 36, 101-108.	1.2	12
188	Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment. Pituitary, 2007, 10, 311-319.	1.6	19
189	Growth hormone assays: current methodologies and their limitations. Pituitary, 2007, 10, 115-119.	1.6	56
190	Indications, limitations and pitfalls in the determination of human growth hormone, IGF-I and their binding proteins. Pediatric Endocrinology Reviews, 2007, 5 Suppl 1, 555-69.	1.2	5
191	Automated Chemiluminescence-Immunoassay for Aldosterone during Dynamic Testing: Comparison to Radioimmunoassays with and without Extraction Steps. Clinical Chemistry, 2006, 52, 1749-1755.	1.5	136
192	Gastrointestinal signalling peptides in obesity. Drug Discovery Today Disease Mechanisms, 2006, 3, 463-470.	0.8	3
193	Plasma- and urine concentrations of nitrite/nitrate and cyclic Guanosinemonophosphate in intrauterine growth restricted and preeclamptic pregnancies. Archives of Gynecology and Obstetrics, 2006, 274, 150-154.	0.8	57
194	Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. Journal of Immunological Methods, 2006, 312, 190-200.	0.6	60
195	Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology, 2006, 154, 467-477.	1.9	148
196	Comparative Pharmacokinetics and Pharmacodynamics of a New Sustained-Release Growth Hormone (GH), LB03002, Versus Daily GH in Adults with GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2926-2930.	1.8	56
197	Short Stature Caused by a Biologically Inactive Mutant Growth Hormone (GH-C53S). Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2493-2499.	1.8	82
198	How Robust Are Laboratory Measures of Growth Hormone Status?. Hormone Research in Paediatrics, 2005, 64, 1-5.	0.8	21

#	Article	IF	CITATIONS
199	Central Administration of Ghrelin and Agouti-Related Protein (83–132) Increases Food Intake and Decreases Spontaneous Locomotor Activity in Rats. Endocrinology, 2004, 145, 4645-4652.	1.4	199
200	Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology, 2004, 29, 185-200.	1.3	42
201	The Distribution and Mechanism of Action of Ghrelin in the CNS Demonstrates a Novel Hypothalamic Circuit Regulating Energy Homeostasis. Neuron, 2003, 37, 649-661.	3.8	1,465
202	Decreasing resistance in the maternal uterine and peripheral arterial system is apparently unrelated to plasma and urinary levels of nitrite/nitrate and cyclic-guanosinmonophosohate during the course of normal pregnancies. Journal of Perinatal Medicine, 2003, 31, 281-6.	0.6	6
203	A New Nonisotopic, Highly Sensitive Assay for the Measurement of Human Placental Growth Hormone: Development and Clinical Implications. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 804-811.	1.8	51
204	Ghrelin drives GH secretion during fasting in man. European Journal of Endocrinology, 2002, 146, 203-207.	1.9	135
205	Quantification of the Soluble Leptin Receptor in Human Blood by Ligand-Mediated Immunofunctional Assay. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2931-2939.	1.8	26
206	Endocrinological effects of mirtazapine in healthy volunteers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 1253-1261.	2.5	30
207	Evaluation of a salivary based combined dexamethasone/CRH test in patients with major depression. Psychoneuroendocrinology, 2002, 27, 385-399.	1.3	32
208	The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology, 2002, 163, 95-101.	1.5	46
209	Changes in Non-22-Kilodalton (kDa) Isoforms of Growth Hormone (GH) after Administration of 22-kDa Recombinant Human GH in Trained Adult Males1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1731-1737.	1.8	64
210	High-Dose Leptin Activates Human Leukocytes Via Receptor Expression on Monocytes. Journal of Immunology, 2001, 167, 4593-4599.	0.4	292
211	Normal Values of Insulin-Like Growth Factor I and Their Clinical Utility in Adults. Hormone Research in Paediatrics, 2001, 55, 100-105.	0.8	37
212	The Response of Molecular Isoforms of Growth Hormone to Acute Exercise in Trained Adult Males1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 200-206.	1.8	75
213	Blockade of the Growth Hormone (GH) Receptor Unmasks Rapid GH-Releasing Peptide-6-Mediated Tissue-Specific Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 590-593.	1.8	55
214	Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant. New England Journal of Medicine, 2000, 342, 1171-1177.	13.9	782
215	Test method: GH. Best Practice and Research in Clinical Endocrinology and Metabolism, 2000, 14, 99-109.	2.2	62
216	Growth Hormone (GH) Receptor Blockade with a PEG-Modified GH (B2036-PEG) Lowers Serum Insulin-Like Growth Factor-I but Does Not Acutely Stimulate Serum GH ¹ . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2098-2103.	1.8	92

#	Article	IF	CITATIONS
217	Detection of doping with human growth hormone. Lancet, The, 1999, 353, 895.	6.3	164